References
- Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 Suppl 1: S99–112
- Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carruci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40
- Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3–10
- Mishra P, Younossi ZM. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr Drug Discov Technol 2007; 4: 133–40
- Sugano M, Fujikawa T, Hiratsuji Y, Hasegawa Y. Hypocholesterolemic effects of chitosan in cholesterol-fed rats. Nutr Rep Int 1978; 18: 531–7
- Han LK, Kimura Y, Okuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int J Obes Relat Metab Disord 1999; 23: 174–9
- Hossain S, Rahman A, Kabir Y, Shams AA, Afros F, Hashimoto M. Effects of shrimp (Macrobracium rosenbergii)-derived chitosan on plasma lipid profile and liver lipid peroxide levels in normo- and hypercholesterolaemic rats. Clin Exp Pharmacol Physiol 2007; 34: 170–6
- Xu G, Huang X, Qiu L, Wu J, Hu Y. Mechanism study of chitosan on lipid metabolism in hyperlipidemic rats. Asia Pac J Clin Nutr 2007;16 Suppl:313–7.
- Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–74
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21
- Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, et al. A model of insulin resistance and Nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169: 846–60
- Lieber CS, Leo MA, Mak KM, Xu Y, Ca Q, Ren C, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004; 79: 502–9
- Nanji AA. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin Liver Dis 2004; 8: 559–74
- Unger RH. Leptin physiology: a second look. Regul Pept 2000; 92: 87–95
- Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319–36
- Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 2005; 39: 237–42
- Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004; 40: 46–54
- Ikejima K, Okumura K, Lang T, Honda H, Abe W, Yamashina S, et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 2005; 33: 151–4
- Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metabolism 2007; 30: 13–9
- Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?. J Hepatol 2006; 44: 253–61
- Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand J Gastroenterol 2007; 42: 1095–101
- Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. J Gastrointest Liver Dis 2006; 15: 363–73